- Fine resolution clustering of TP53 variants into functional classes predicts 1 2 cancer risks and spectra among germline variant carriers
- 3
- Emilie Montellier, PhD (1), Nathanaël Lemonnier, PhD (1), Judith Penkert, MD (2), 4
- Claire Freycon, MD (1,3,4), Sandrine Blanchet, MSc (1), Amina Amadou, PhD (1,5), 5
- Florent Chuffart, PhD (1), Nicholas Fischer, PhD (6), Maria Isabel Achatz, MD, PhD 6
- 7 (7), Arnold Levine, PhD (8), Catherine Goudie, MD (4), David Malkin, MD, PhD (6),
- Gaëlle Bougeard, PhD (9), Christian Kratz, MD (2) and Pierre Hainaut, PhD (1)* 8
- 9

Affiliations: 10

- 11 (1) Univ. Grenoble Alpes, Inserm 1209, CNRS 5309, Institute for Advanced
- Biosciences, F38000, Grenoble, France 12
- 13 (2) Pediatric Hematology and Oncology, Hannover Medical School, Hannover,
- Germany 14
- 15 (3) Centre Hospitalier Universitaire Grenoble Alpes. Department of Pediatrics
- (4) Department of Pediatrics, Division of Hematology-Oncology, Montreal Children's 16
- Hospital, McGill University Health Centre, Montreal, Quebec, Canada 17
- (5) Department of Prevention Cancer Environment, Centre Léon Bérard, Lyon, France 18
- (6) Genetics and Genome Biology Program, The Hospital for Sick Children; University 19
- of Toronto, Toronto, Ontario, Canada 20
- (7) Department of Oncology, Hospital Sírio-Libanês, São Paulo, Brazil 21
- (8) Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ 22
- (9) Department of Genetics, Normandy Center for Genomic and Personalized 23
- 24 Medicine, University Hospital, Rouen, France; Normandie Univ - UniRouen, Inserm
- 25 U1245, Rouen, France
- 26

27 **Correspondence:**

- 28 * corresponding author:
- 29 Institute for Advanced Biosciences,
- Univ. Grenoble Alpes, Inserm 1209, CNRS 5309 30
- Site Santé, Allée des Alpes 31
- F38700, La Tronche, France 32
- pierre.hainaut@univ-grenoble-alpes.fr 33
- _NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Tel +33 6 20 38 05 47 34

35 ABSTRACT

36

37 Li-Fraumeni syndrome (LFS) is a heterogeneous predisposition to a broad spectrum of cancers caused by pathogenic *TP53* germline variants. We have used a clustering 38 approach to assign missense variants to functional classes with distinct quantitative 39 and qualitative features based on transcriptional activity in yeast assays. Genotype-40 phenotype correlations were analyzed using the germline TP53 mutation database (n 41 = 3,446) and validated in three LFS clinical cohorts (n= 821). Carriers of class A 42 43 variants recapitulated all traits of fully penetrant LFS (median age at first diagnosis = 28 years). Class B carriers showed a less penetrant form (median = 33 years, p < 0.05) 44 dominated by adrenocortical and breast cancers. Class C or D carriers had attenuated 45 phenotypes (median = 41 years, p < 0.001) with typical LFS cancers in C and mostly 46 47 non-LFS cancers in D. This new classification provides insight into structural/functional features causing pathogenicity. 48

49

INTRODUCTION 50

51

52 Li-Fraumeni syndrome (LFS; Mendelian Inheritance in Man [MIM] #151623) is an autosomal dominant cancer predisposition syndrome associated with a high lifetime 53 risk of a broad spectrum of cancers caused by pathogenic or likely pathogenic (P/LP) 54 TP53 germline (or mosaic) variants, 80% of which are missense ¹. Typically, LFS 55 occurs in three phases, (1) the childhood phase (0-18 years), characterized by a 56 quartet of early life cancers (adrenocortical carcinoma, ACC; choroid plexus tumor, 57 CPT; medulloblastoma, MB, and rhabdomyosarcoma, RMS, all of which occur almost 58 exclusively before age ten years), and a high risk of soft tissue sarcoma (STS), 59 60 osteosarcoma (OS), and central nervous system tumors (CNS) in adolescence; (2) the early adult phase, characterized by premenopausal breast cancer (PBC), multiple STS 61 and CNS; and (3) the late adult phase, characterized by lung adenocarcinoma (LUAD), 62 STS, colorectal cancer and prostate cancer². Clinical definitions are traditionally based 63 on classic LFS criteria³, whereas revised Chompret criteria⁴ are aimed at identifying 64 patients for TP53 mutation testing, covering both childhood and adult common 65 presentations of LFS. A definition of the phenotypic spectrum of LFS has been 66 proposed, encompassing (1) phenotypic LFS, defined by the absence of a germline 67 68 TP53 variant in persons/families meeting clinical LFS criteria, i.e., classic LFS or

Chompret Category A testing criteria; (2) LFS, defined by the presence of a TP53 69 variant in persons/families meeting LFS testing criteria or with cancer < 18 years; (3) 70 71 attenuated LFS (aLFS), defined by the presence of a TP53 variant in a person/family 72 with cancer \geq 18 years who does not meet LFS testing criteria; and (4) incidental LFS, 73 defined by the presence of a TP53 variant in a person/family without a history of cancer 74 ⁵. This phenotypic definition provides a framework to investigate genotype-phenotype 75 correlations by classifying TP53 variants according to their pathogenicity.

76

The p53 protein is a multi-functional transcription factor regulating a complex network 77 of cellular and systemic anti-proliferative responses ^{6–8}. Loss of these functions, often 78 caused by inactivating missense mutations in the TP53 gene, impairs several 79 coordinated mechanisms of growth suppression that normally operate to counteract 80 carcinogenesis⁹. The main functional feature of tumor-associated somatic mutations 81 is the disruption of DNA binding and transactivation capacity of the p53 tumor 82 suppressor protein, either by direct mutation and structural alteration of the DNA-83 binding domain (DBD), or by destabilization of the oligomerization domain required for 84 high-affinity DNA-binding (Loss of Function, LOF). Stable mutant proteins can also 85 86 exert dominant-negative effects (DNE) over wild-type allele products and have also been proposed to exert a number of pro-oncogenic gain of function (GOF) effects 87 88 documented in experimental cell and animal models ¹⁰, the phenotypic consequences of which remain unclear in the context of LFS. Systematic large-scale studies have 89 90 assessed the impact of thousands of missense variants on biochemical and biological p53 protein functions in yeast or cell-based experimental assays ^{11–13}. This wealth of 91 92 information, as well as carriers' phenotypic traits, is used by the ClinGen TP53 expert 93 panel inform variant interpretation for clinical to purposes (https://clinicalgenome.org/affiliation/50013/)¹⁴. Of particular interest among functional 94 datasets is the TP53 variant transactivation dataset developed over 20 years ago by 95 C. Ishioka et al. using a yeast-based functional assay ¹². This assay analyzed the 96 transactivation capacity of a panel of 2,314 variants towards synthetic reporters 97 controlled by eight different p53 DNA response elements (p53RE). Thus, this dataset 98 provides the equivalent of eight different "mugshots" for each variant, revealing both 99 quantitative and qualitative features that capture subtle variations in their capacity to 100 101 bind and transactivate different sequences matching the p53 DNA-binding consensus. 102

103 In this study, we described and tested a new classification of *TP53* missense variants 104 based on a revisited analysis of Kato's yeast-based transactivation (YTA) data (Figure 105 **1**, graphical abstract). We have applied an iterative clustering approach to separate TP53 missense variants into four classes (A, B, C, D) as compared to 106 107 nonsense/frameshift variants (class 0) that are considered as completely inactivating the p53 protein. Mapping these classes on phenotypic LFS data from the public 108 repository of germline TP53 variants curated at NCI (https://tp53.isb-cgc.org/) revealed 109 that each class is associated with defined phenotypic traits within the LFS spectrum. 110 111 Our results provide a refined resolution of genotype-phenotype correlations in LFS as 112 well as insights on structural/functional features that specify variant pathogenicity.

113

RESULTS & DISCUSSION 114

115

TP53 variant clustering 116

117

An iterative hierarchical Ward's clustering method was used to interrogate the 118 119 missense variant dataset developed by Ishioka and collaborators in yeast based 120 functional assays ¹². We identified 16 iterative clusters of various sizes based on variant similarities in their capacity to differentially activate eight promoters containing 121 different versions of p53 DNA consensus elements (from 613 variants in Cluster 2 2 1 122 to 5 variants in Cluster 3) (Figure S1 and Figure S2A). Each cluster differed by the 123 quantitative and qualitative features of their transcriptional activity, ranging from 124 complete loss of activity towards all promoters (cluster 1 1 1, "triple 1") to enhanced 125 transcriptional activity (compared to wild-type p53) towards at least some promoters 126 (cluster 3, "supertrans"), with a broad diversity of clusters with intermediate qualitative 127 128 and quantitative features.

129

130 To map these clusters onto the LFS tumor spectrum, we grouped them into four classes (A to D), broadly reflecting a gradient of activity with A having the lowest overall 131 transcriptional activity and D the highest, and B and C displaying intermediate and 132 heterogeneous activities towards different reporters (Figure S2). The list of the 2,314 133 134 TP53 missense variants and the corresponding clusters and classes is presented in Table S1. Classes showed clear differences in variant distribution within the p53 135 136 protein structure (Figure 2A and S3) and in their predicted structural/functional effects

(Figure S4). When compared with biophysical prediction scores (SIFT, AGVGD) ^{15,16} 137 and integrative structural and functional scores ¹⁷, classes highlighted a gradient from 138 A to D, with A and B being enriched in deleterious and non-functional features while C 139 140 and D were enriched in non-deleterious and functional features. Class A included all 141 common TP53 cancer mutation hotspots and was enriched in variants at residues 142 located within the surface of the p53 protein in direct contact with DNA, in structural elements supporting the DNA binding surface, or in structural motifs required for the 143 cohesion of the p53 tetramerization domain. Class B included variants mapping to the 144 145 DBD of p53, albeit at different residues than class A, mostly located within defined 146 sections of the beta-sheets that constitute the scaffold of the DBD as well as in loops 147 exposed at the surface of the protein but not within its DNA-binding surface. Class C and D were enriched in variants that mapped to the N-terminus or to the extreme C-148 149 terminus of p53. Class C, in particular, was enriched in variants at residues of the C-150 terminal regulatory domain with multiple post-translational regulatory sites poorly 151 represented in other classes.

152

153 We next mapped the distribution of classes A-D in three TP53 variant datasets: cancer-154 related germline variants (NCI; <u>https://tp53.isb-cgc.org/</u>), cancer related somatic variants (COSMIC; https://cancer.sanger.ac.uk/cosmic) and non-cancer related 155 germline variants (gnomAD; https://gnomad.broadinstitute.org/) (Figure 2B). Class A 156 variants were enriched by factors of 4.5 and 3.3 fold in the COSMIC and NCI datasets, 157 158 respectively but were counter-selected (0.2 fold) in the gnomAD dataset. Likewise, albeit to a lesser extent, class B variants showed positive selection in COSMIC (1.1) 159 and NCI (1.3) datasets, but not in gnomAD (0.2). In contrast, class D variants were 160 enriched in gnomAD (1.8) and counter-selected in COSMIC (0.1) and NCI (0.2), 161 162 whereas class C was not enriched in any of the datasets. These results are compatible with the notion that classes A to D correspond to a gradient of cancer-related p53 163 164 dysfunction.

165

Variant classes are associated with distinct phenotypic patterns within the LF 166 167 spectrum

168

169 To determine whether variant classes could predict tumor phenotypes within the broad 170 LF spectrum, we analyzed lifetime cancer accrual and tumor patterns using data

compiled in the NCI germline TP53 mutation database (https://tp53.isb-cgc.org/) ¹⁸. 171 This database assembles information retrieved from the literature on 3,446 individuals 172 173 (1,522 families) with germline *TP53* variants (4,031 cancer diagnoses). As a basis for comparison, we added a class "zero" (0) that included variants considered as "null" for 174 p53, i.e., non-missense variants (nonsense, frameshift,) that disrupt the production of 175 a functional p53 protein (Figure S5). Class 0 thus includes variants considered to have 176 completely lost wild-type p53 function. Figure 3A shows that class A variants were 177 found in 1426 (53%) patients, followed by class 0 (552, 21%), B (290, 11%), C (242, 178 179 9%), and D (171, 6%). Gender distribution differed among classes, with a lower 180 proportion of males in classes B, C and D (31.4%, 26.7%, and 32%, respectively) than 181 in classes 0 and A (40.9% and 40.6%, respectively) (Figure 3B). With respect to 182 lifetime cancer accrual, classes 0 and A were associated with the most severe profiles 183 (median age at first diagnosis = 28 years) (Figure 3C-E). Classes C and D were associated with attenuated accrual profiles (median age = 41 years), whereas class B 184 185 showed an intermediate and distinct profile (median age = 33 years), characterized by rapid accrual during childhood (similar to classes A and 0) and slower accrual during 186 187 adolescence and adulthood. This gradient of pathogenicity was reflected in the 188 proportion of carriers with multiple cancers as well as cancer free (Figure 3F-G) and was consistent with current definitions of clinical phenotypes (Figure I-J). Of note, 189 190 Variants in established cancer predisposition genes other than TP53 were more 191 frequently found in carriers of class D variants than in carriers of any other variant class 192 (Figure 3H).

193

Comparison across classes revealed statistically significant differences in tumor 194 195 patterns (Figure 4, Table S2, Figures S6 and S7). Classes 0 and A shared topological 196 and morphological tumor patterns that recapitulated the broad phenotype of the LF spectrum. This included all LFS "signature" cancers such as childhood ACC, CPT, 197 198 RMS, and MB, teenage OS, and early adulthood breast phyllodes cancers. There 199 were, however, small but statistically significant differences between 0 and A, the latter presenting with a higher proportion of brain cancers (BR) (RR = 1.53, 95% CI [1.16-200 2.05]), including in particular CPT (Figure 4B-C, Table S2 and Figure S6) compared 201 202 to class 0. This observation suggests that, whereas in most tissues class A variants do not convey a stronger predisposition than class 0 (LOF), they could exert limited 203 204 dominant GOF effects by accelerating tumor onset in specific tissues (e.g. CPT)

without changing the overall phenotypical pattern of LFS. Importantly, we could not
identify a subset of variants within class A that would be responsible for these effects
(e.g. class A variants overrepresented in CPT compared to other cancers). Overall,
these observations suggest that such GOF effects in LFS depend upon cell and tissue

- 209 context rather than upon specific variant structural and functional properties.
- 210

Compared to 0 and A, class B presented with a slightly smaller proportion of many of 211 the cancers that define the LF spectrum (Figure 4B-C and Figure S6), with the notable 212 213 exception of ACC (RR B vs A = 2.74 (95% CI [1.78;4.143.90]; RR B vs 0 = 3.12 (95% 214 CI [1.84-5.34]) (**Table S2**). In class B, ACC was by far the most common cancer form 215 in children (up to the age of 10), accounting for the fact that cancer accrual in early life 216 was as rapid in that class than in classes 0 or A (**Figure 3C**), despite the relative rarity 217 of some of the other childhood "signature" LFS cancers in class B carriers (i.e., RMS, MB) (Figure S6). Compared to A, class B also showed a higher proportion of carriers 218 219 who were cancer-free (Figure 3G) as well as differences in the predominant morphologies of CNS (glioblastomas) (Figure 4B, Figure S6). As a result, carriers of 220 221 class B variants showed a slightly delayed median age of tumor onset as compared to 222 classes 0 and A, but a similar pattern of cancer accrual during childhood. Thus, class B identified variants with a slightly distinct risk profile within the LF spectrum. These 223 224 variants were mostly distributed within structural motifs of the DBD that are not in contact with DNA and showed less severe structural and functional features than class 225 A. Compared to other classes, class B variants also showed a remarkable 226 heterogeneity in their capacity to transactivate different YTA promoters. Overall, these 227 observations suggest that the more distinct effects of class B variants are due to the 228 229 retention of partial and selective p53 transcriptional activity. On the other hand, the 230 high prevalence of ACC in carriers of class B variants suggests that perinatal adrenal cortical cells are exquisitely sensitive to wild-type p53 dosage and that variants 231 232 mediating only partial loss of wild-type p53 activity may suffice to enhance the risk of 233 early ACC.

234

Class C contains less penetrant variants, which nevertheless predispose to cancers
typical of the LF spectrum, in particular ACC (Figure 4B-C and Figure S6). Compared
to 0, A and B, class C presented with an attenuated risk of all cancers characterizing
the LF spectrum, except ACC (RR C vs A = 2.05 (95%CI [1.20-3.34]) and breast

cancers (BC) (RR C vs A = 1.75 (95% CI [1.32-2.31]) (Figure 4B-C, Figure S6, Table 239 **S2**). In particular, class C carriers rarely presented with OS compared to class A or 0 240 241 carriers (Figure S6). Likewise, CPC and RMS were vastly underrepresented, and MB were absent (Figure S6). Class C also presented with a higher proportion of cancer-242 243 free carriers than any other class (Figure 3G). Thus, class C appears to be associated with a cancer risk that only partially recapitulates the LF spectrum. Interestingly, this 244 class included two founder variants qualified as "hypomorphs", R337H (Brazilian-245 centric) ¹⁹ and Y107H (African-centric) ²⁰, which retain partial wild-type p53 activities 246 247 when tested in standard conditions *in vitro* but nevertheless specify a significant risk for diverse cancers of the LF spectrum in both children and adults. It has been 248 249 suggested that these variants may require synergistic alterations in other pathways to 250 express their full pathogenic potential. This hypothesis is supported by the discovery 251 that. in R337H carriers, an inactivating variant of the putative tumor suppressor XAF1 (E134*/Glu134Ter/ rs146752602) enhances the risk of developing 252 253 sarcomas ²¹. Thus, class C may be enriched in incompletely inactivating variants that require genetic, epigenetic, or metabolic/biochemical complementation to express their 254 255 full pathogenic potential.

256

257 Class D presented with the most attenuated pattern within the LF spectrum. "Signature" LF cancers such as early ACC, CPT, MB, OS, and phyllodes tumors of the 258 259 breast were, if not completely absent, significantly less represented than in A, B or C (Figure 4B-C, Figure S6). In contrast, the most represented cancer types in D were 260 malignancies involving the hematopoietic system, the most common form of sporadic 261 neoplasia in children, independent of germline status. Class D variants retained guasi-262 263 wild-type p53 transcriptional properties for at least half of the YTA promoters tested, consistent with their ClinVar annotation as benign or likely benign (B/LB). In line with 264 265 these data, class D carriers also more frequently harbored pathogenic variants in other 266 established cancer predisposition genes than carriers of any other class (Figure 3H). 267 These observations suggest that carrying a class D variant may not in itself predispose to LFS. However, it cannot be excluded in specific contexts (e.g. inheritance of other 268 269 cancer predisposing variants or genetic modifiers), some class D variants may contribute to enhance the risk of LF spectrum cancers. Thus, great care should be 270 exercised when considering such variants in genetic counselling. 271

The overall cancer phenotypes of each variant class are summarized in a heatmap 273 (Figure 4C), highlighting an LF tumor-specific phenotypic gradient from classes 0 and 274 275 A to class C. Classes A and 0 were associated with the most severe forms of LFS, class B identified a distinct, slightly less penetrant form, with ACC as the most frequent 276 early life cancer, class C was correlated to an attenuated form nevertheless 277 predisposing to cancers typical of the LF spectrum (ACC, BC), whereas class D did 278 not appear to confer a risk for LFS cancers. 279

Dissecting variant classes using cell-based functional scores

280

281

282

283 Despite their high sensitivity and selectivity for distinct p53RE, YTA screens may lack 284 the specificity of phenotypic screens in human cells addressing physiologically 285 meaningful p53 functionalities. We thus sought to determine whether the functional 286 scores obtained in systematic human cell-based assays were consistent with our YTA 287 classes and could identify additional groups of variants associated with distinct LF phenotypes. First, the stability and coherence of YTA classes was challenged with the 288 289 functional scores developed by Giacomelli et al.¹¹ (phenotypic selection model) and Kotler et al. ¹³ (relative fitness score). **Figure 5** shows that these functional scores were 290 broadly consistent with YTA classes, with A having the highest and D the lowest 291 292 median scores. However, individual variant scores were widely distributed within each 293 class, suggesting that YTA classes may contain variants that differ by their functional 294 properties when overexpressed in human cells. To further assess this heterogeneity, we separated variants in each class into groups according to the quartiles of their 295 human cell-based functional scores (Figures S8, S9). Results show that cancer 296 297 accrual in class A carriers was similar across all quartiles and thus independent of 298 human cell-based scores. Whereas heterogeneity was found for classes B, C and D, 299 it reached statistical significance only for class C (p < 0.0001, Giacomelli's phenotypic 300 selection model; p = 0.0073, Kotler's relative fitness score), highlighting that this class 301 contains variants that are more functionally heterogeneous than variants in other classes. Similarly, stability analyses using TP53 PROF, an integrative computational 302 score ¹⁷, did not show any additional benefit of using this score for stratifying variants 303 according to their pathogenicity within each of the YTA classes (Figure S10). Overall, 304 these results show that YTA classes were remarkably robust and sensitive in predicting 305 306 cancer accrual and cancer phenotypes in germline TP53 variant carriers.

307

Clinical significance of YTA classes 308

309

ClinVar expert panel annotations (https://clinicalgenome.org/affiliation/50013/) are 310 based on expert consensus review of genotype/phenotype correlations and are the 311 current standard for interpreting TP53 germline variants for clinical purposes ¹⁴. 312 However, these annotations cover only a proportion of all missense variants in the NCI 313 germline dataset. We thus assessed the concordance between YTA classes and 314 315 ClinVar expert panel as a first step to determine whether YTA classes could assist in 316 the clinical evaluation of variants that have not yet been annotated to date. Figure 6A 317 shows that YTA classes were broadly concordant with expert panel annotations, with 318 A and B classes mostly represented among P/PL variants and C and D classes mostly 319 represented among B/LB variants. The only exception was D49H, a class A variant which was annotated as LB by ClinVar. Of note, there is only a single family (2 patients) 320 321 with this variant documented in the NCI germline dataset. This family matched phenotypic criteria for TP53 mutation testing (Chompret's criteria; embryonal RMS of 322 323 the cervix at 2 years and Hodgkin's lymphoma at 15 years) ²². D49H has also been 324 reported in 6 Japanese patients with family history of cancer, one of whom matched Chompret's criteria ²³. This patient carried another germline class A TP53 variant, 325 A159D. Overall, these observations suggest that D49H should be considered with 326 327 caution as a rare, potentially pathogenic variant.

328 Interestingly, variants annotated as "Uncertain Significance" (VUS) were predominantly class C variants, followed by class B and D variants, suggesting that 329 YTA classes may help in resolving ambiguities in variant annotations. Furthermore, 330 variants annotated by the expert panel could be perfectly separated on the basis of 331 332 cancer accrual according to YTA classes (p < 0.0001), recapitulating the distinct accrual pattern of each class (e.g the difference in cancer accrual between class A and 333 334 class B variant carriers). (Figure 6B and 3C). These results suggest that YTA classes 335 are remarkably consistent with expert panel annotations.

336

Next, we evaluated to which extend YTA classes could predict cancer accrual in 337 subjects carrying variants not annotated by the expert panel. Within classes A, B and 338 C, cancer accrual in carriers of non-expert panel variants was almost perfectly aligned 339 340 with the one of expert panel curated variants (Figure 6C).

medRxiv preprint doi: https://doi.org/10.1101/2023.12.23.23300440; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

341

To further assess the usefulness of YTA classes in a clinical context, we examined 342 343 cancer accrual and tumor patterns according to classes in three cohorts of carriers 344 recruited in different high risk cancer predisposition clinics in Germany (n = 146, LFS Registry in Hannover), France (n = 578, French LFS Cohort) and Canada (n = 97, 345 Toronto LFS Cohort). These cohorts are maintained and annotated mainly 346 independently of the NCI germline dataset. Figure 7 shows that, in each of the cohorts, 347 YTA classes correctly predicted cancer accrual and distinguished among carriers with 348 349 quantitative and qualitative differences in LF spectrum. In all three cohorts, class A 350 carriers presented the most severe phenotype (similar to class 0 in the German and 351 Canadian cohort). Compared to A, class B carriers had a distinct and less penetrant 352 phenotype, characterized by high risk of early life ACC and slightly delayed overall 353 cancer accrual. Class C carriers often had attenuated phenotypes, nevertheless 354 including cancers typical of the LF spectrum (i.e., ACC and PBC) but excluding most 355 other typical LF childhood cancers, whereas in class D tumor patterns tended to be 356 more heterogeneous, with the majority of carriers not matching LF spectrum definitions 357 (Figure S11). Overall, these observations support that YTA classes can help to predict 358 specific patterns of risk in germline carriers and could be particularly helpful for assessing the risk of novel variants as well as variants not yet annotated by expert 359 360 panels or ClinVar.

361

362 CONCLUSIONS

363

This new classification of TP53 missense variants into 4 classes supports a robust 364 interpolation between genotypes (variant characteristics) and phenotypes (cancer risk 365 366 and spectrum). The classification is based on quantitative and qualitative similarities between variants in a yeast-based transcriptional assay. Whereas the yeast readout 367 368 is based on variants' interaction with synthetic p53RE (DNA binding capacity), YTA 369 classes correctly separate severe from mild or benign variants in all structural domains 370 of the p53 protein, including transactivation domain, DBD and tetramerization domain. The coherence and robustness of YTA classes is demonstrated by the fact that 371 372 implementing human cell-based functional scores within YTA classes did not break them into further subgroups, suggesting that yeast-based readouts are precise and 373 374 sensitive enough by themselves to allocate variants to clinically meaningful groups.

375 Overall, these observations imply that, collectively, the 8 yeast-based readouts 376 available for each variant can be used as sensitive "mugshots" for variant risk 377 assessment.

378 This classification provides new insights into the concept of attenuation within the LF 379 spectrum ⁵. The term aLFS has been coined to identify an LF phenotype defined by the presence of a germline P/LP TP53 variant in a person with any cancer who does 380 not meet LFS genetic testing criteria and has no cancer diagnosed before age 18 381 years. Our analysis did not identify a specific YTA class matching this phenotypic 382 383 definition. Rather, we observed a gradient in the proportion of individuals with aLFS 384 phenotype from class 0 or A (< 17-21%) to class C or D (> 50-61%) (Figure 3J). 385 Remarkably, even among carriers who met LFS genetic testing criteria, YTA classes 386 underscored a gradient of phenotypic attenuation, with carriers of B or C variants 387 presenting, on average, with a less severe phenotype than carriers of A or 0 variants. 388 Another key message is that risk attenuation in relation to YTA classes does not obey to a unique, linear rule for all cancers that characterize the LF spectrum. In particular, 389 390 carriers of B or C variants retain a risk for early ACC at least equal to classes 0 and A, 391 supporting that predisposition to this cancer can be high even with relatively mild TP53 392 variants. In contrast, other "signature" LF cancers such as OS, CPT, MB or RMS, were 393 remarkably more prevalent in carriers of 0 or A than in carriers of B, C or D variant 394 classes. A limitation of this study is that it does not take into account the fact that at 395 least some mutations causing missense variants may also cause aberrant mRNA 396 splicing patterns, resulting in loss of p53 protein expression. Such effects may confer 397 greater severity to variants currently solely interpreted as missense. So far, these effects on splicing have not been evaluated in systematic functional assays. Overall, 398 our integrative genotypic/phenotypic analysis provides a new angle to predict individual 399 400 and familial risk in germline variant carriers, as well as a basis to identify hypomorphic 401 variants that require genetic or epigenetic modification to express their full pathogenic 402 potential.

403 MATERIAL AND METHODS

404

Iterative clustering on transactivation data. We retrieved transactivation scores
from 2,314 *TP53* variants ¹² on eight *TP53* promoters (WAF1nWT, MDM2nWT,
BAXnWT, h1433snWT, AIP1nWT, GADD45nWT, NOXAnWT, P53R2nWT). We

performed hierarchical Ward clustering in R v3.6.1 with Euclidean distance, and 408 409 arbitrarily chose three clusters. We performed a second iteration of clustering in the 410 sub-clusters including more than 50 mutations. Up to three layers of clustering iterations were processed. A total of 16 distinct clusters were thus defined. 411 412 Dendrograms were retrieved with *dendextend* package, and heatmaps were built using 413 pheatmap package.

414

YTA classes consolidation. Final groups of clusters (YTA classes) were defined via 415 416 the following approach: the most disrupted variants (cluster 1_1_1) were assigned to class A; variants of the upper layer (layer 1 1 except cluster 1 1 1) were defined as 417 418 class B; variants of the next upper layer (layer 1 except the layer 1_1) were defined as 419 class C; finally, the less disrupted variants (all variants except layer 1) were defined as 420 class D.

421

422 Confrontation of YTA classes with existing scores for TP53. We confronted our classes to various scores attributed to TP53: the transactivation classes as previously 423 424 defined by the analysis of transactivation in yeast assays ¹², the Sorting Intolerant from Tolerant (SIFT) database (<u>https://sift.bii.a-star.edu.sg</u>) ¹⁶, the Align Grantham Variation 425 426 Grantham Deviation (AGVGD) database (<u>http://agvgd.hci.utah.edu</u>) ¹⁵, the TP53 prediction of functionality (TP53_PROF)¹⁷, the *TP53* functionality scores obtained in 427 428 human cell lines ^{11,13} and the ClinVar database which aggregates information about 429 genomic variation and its relationship to human health (https://www.ncbi.nlm.nih.gov/clinvar)²⁴. The confrontation of the classes with the 430 various TP53 scores was performed using Pareto Plot or Pie Chart representations for 431 categorical values and Scattered Plots and Violin Plots for numerical values (R, ggplot2 432 433 package).

434

Structural mapping of YTA classes. The distribution of *TP53* mutated residues along 435 436 the TP53 sequence and domains was analyzed for each YTA class. Heatmaps were used to highlight the pattern of distribution of variants along TP53 sequence in the 437 different YTA classes (R, package *pheatmap*). The proportion of variants within each 438 TP53 domain is depicted using cumulative histograms (R, package ggplot2). The 439 localization of mutations in the p53 protein structure was assessed using the software 440 ChimeraX²⁵ (https://www.cgl.ucsf.edu/chimerax) together with PDB files of the TP53 441

binding domain 3KMD 26 and the *TP53* tetramerization domain 1C26 27 , as well as the alpha-fold modelized structure 28 .

444

YTA classes distribution in datasets. The occurrence of *TP53* variants assigned to 445 446 YTA classes was assessed in different databases: tumor-based variants in the Cosmic database v97 (https://cancer.sanger.ac.uk/cosmic)²⁹, normal sample-based variants 447 in the gnomAD database v3.1.2 (https://gnomad.broadinstitute.org) ³⁰, and TP53 448 germline variants database R20 released in July 2019 and hosted at the NCI 449 450 (https://tp53.isb-cgc.org) ¹⁸. We used the protein mutation information in the databases to analyze the distribution of variants into YTA classes. Pie charts are used to show 451 452 distribution of variant classes in the different databases, and numerical counts are 453 indicated (R, gaplot2 package).

454

Selection of individuals from the LF spectrum database. We analyzed the YTA 455 456 classes on clinical data from the LF spectrum database R20 (germline TP53 variants), released in July 2019 and hosted at the NCI (https://tp53.isb-cgc.org) ¹⁸. This database 457 458 recapitulates clinical data of patients carrying TP53 germline variants. The database 459 contains data from 3,446 individuals (from 1,522 families) reported in the scientific 460 literature since 1990. Individuals carrying several *TP53* variants were excluded from 461 our analysis because of complexity to determine the contribution of individual variants in these patients. Also, individuals carrying the TP53 p.R337H Brazilian variant who 462 were not recruited through familial history of cancer were removed, because of bias of 463 analysis (in column Ref ID: 138, 196, 259, 323 and 400 were selected in the LF 464 spectrum database). Individuals carrying *TP53* missense variants were dispatched in 465 groups corresponding to the YTA classes (A, B, C, D). The remaining individuals, 466 467 carrying non-missense variants were selected based on the type of effect of the variant in order to build a class of reference containing non-functional (LOF) variants. We only 468 469 kept nonsense and frameshift (ft) variants (from column "Effect") to consolidate a null 470 class (named class 0) corresponding to disruption of the full-length protein.

471

Genotype-Phenotype correlations of YTA classes within the LF spectrum
database. Lifetime cancer accrual for the YTA classes was assessed using the age of
first cancer onset or the cancer-free age of an individual. Patients without age
indication were not considered for this analysis. The age of median cancer accrual

(and confidence intervals at 95%) was extracted and a Log-Rank Mantel-Cox test was 476 477 run to assess the significance of differences between groups. These analyses were 478 performed using R and the survival and survminer packages. Information about 479 individuals' sex was retrieved in the corresponding column (Sex). The proportion of individuals with multiple cancers versus individuals with one cancer was assessed for 480 each YTA class. The proportion of cancer-free individuals compared to individuals with 481 cancer was assessed for each class. Tumor distribution was determined in the YTA 482 classes by analyzing all tumors described in the dataset (primary and secondary 483 484 malignancies). We used the topology (organs) and the morphology (subtypes) 485 information available in the LF spectrum database, and we consolidated groups based 486 on organs of interest for the study of LFS (adrenal gland, brain, bone, soft tissue, 487 breast, hematopoietic system, and the mix of all other organs) as well as specific 488 cancer types (ACC, OS, CPT, MB, glioblastoma, phyllodes tumors, and RMS). Graphical representation of proportions of tumor types was performed using R 489 490 (package *ggplot2*). Distribution of tumor topology was compared between YTA classes by performing a Khi2 test (multiple pairwise comparison) to obtain a risk ratio, 491 492 confidence intervals at 95% and an associated adjusted p-value, using R software. 493 Mapping of age-specific tumor distribution within YTA classes was assessed by 494 generating rain-cloud plots (R, package ggplot2). Finally, the relationship between YTA 495 classes and the clinical definitions of LFS was evaluated using the LFS spectrum 496 classification ⁵ and the column "Class" from the IARC/NCI database, to build bar-plots 497 of proportions of individuals within each clinical class.

498

Challenging YTA classes with other functional scores. YTA classes were 499 500 separated based on the *TP53* functionality scores obtained in human cell lines ^{11,13}. 501 For each YTA class, *TP53* variants were separated into four groups by quartile values. The 1st quartile corresponds to lower scores and the 4th quartile corresponds to higher 502 503 scores (most disrupted functionality of p53). YTA classes were also separated based 504 on the TP53 prediction of functionality (TP53_PROF, Deleterious and Non-17 505 Deleterious) and the ClinVar database annotation (https://www.ncbi.nlm.nih.gov/clinvar)²⁴. Cancer accrual of the subgroups of each YTA 506 class was analyzed and the median age and statistical differences were extracted 507 similar to YTA class comparison. 508

Validation cohorts. Three validation cohorts originating from three different clinics 510 were used to verify the consistency of our observations for the YTA classes. 511

- 512 The "LFS Registry in Hannover", Germany, recruits patients with a previously established diagnosis of LFS. Only patients carrying pathogenic or likely 513 pathogenic variants (according to Fortuno criteria) are included. 514
- The "French LFS Cohort" has included germline missense TP53 variants from 515 the French registry (Rouen, France) identified in cancer patients who benefited 516 from TP53 analysis. 517
- 518 The "Toronto LFS Cohort", Canada, is a multi-institutional collection of data from -519 patients and families carrying germline pathogenic variants that were referred 520 to The Hospital for Sick Children.
- 521

522

523 **AUTHOR CONTRIBUTIONS**

524 EM, NL and PH conceived and designed the study. PH supervised research. NL 525 performed hierarchical clustering. EM performed bioinformatic analysis and graphical 526 representations with the help of SB. EM analyzed genotype-phenotype correlations 527 with the help of CF. JP, CK, GB, NF and DM provided clinical data. AA and FC assisted EM with statistical analyses. JP, CK, GB, NF, DM, MIA, AL and CG contributed to the 528 529 discussion and interpretation of variant classes. EM and PH wrote the manuscript. All 530 authors critically revised the manuscript for important intellectual content and approved 531 the version for publication.

532

ACKNOLEDGMENTS 533

EM was a recipient of a European MSCA individual fellowship (846806) and a 534 Foundation ARC (France) postdoctoral fellowship. This work is supported by the IDEX 535 536 of University Grenoble Alpes (LIFE project) and by the ERiCAN program of Foundation 537 MSDAvenir (France). CPK is supported by the BMBF ADDRess (01GM2205A) and by the Deutsche Kinderkrebsstiftung (DKS2021.25). 538

539

540 ABBREVIATIONS

- 541 ACC: Adrenal Cortical Carcinoma
- 542 AGVGD: Align Grantham Variation and Grantham Deviation
- 543 aLFS: attenuated LFS

- **BC: Breast Cancer** 544
- 545 **BR: Brain Cancer**
- 546 B/LB: Benign or Likely Benign
- **CNS: Central Nervous System Tumors** 547
- **CRC: Colorectal Cancer** 548
- COSMIC: Catalogue of Somatic Mutations in Cancer 549
- **CPT: Choroid Plexus Tumors** 550
- **DBD: DNA Binding Domain** 551
- 552 DNE: dominant-negative effect
- GOF: Gain of Function 553
- 554 gnomAD: Genome Aggregation Database
- 555 LF: Li-Fraumeni
- 556 LFS: Li-Fraumeni Syndrome
- LOF: loss of function 557
- 558 LUAD: lung adenocarcinomas
- MB: Medulloblastoma 559
- 560 **OS:** Osteosarcoma
- 561 PBC: Premenopausal Breast Cancer
- P/LP: Pathogenic or Likely Pathogenic 562
- 563 P53RE: p53 Response Elements
- 564 RMS: Rhabdomyosarcoma
- SIFT: Sorting Intolerant From Tolerant 565
- STS: Soft Tissue Sarcoma 566
- 567 VUS: Variants of Unknown Significance
- YTA: Yeast Transactivation Assay 568

569 REFERENCES

- 1. Bougeard, G. et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J 570
- 571 Clin Oncol 33, 2345–2352 (2015).
- 572 2. Amadou, A., Achatz, M. I. W. & Hainaut, P. Revisiting tumor patterns and penetrance
- in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. *Curr* 573
- 574 Opin Oncol 30, 23-29 (2018).

- 575 3. Li, F. P. *et al.* A cancer family syndrome in twenty-four kindreds. *Cancer Res* 48,
- 576 5358-5362 (1988).
- 577 4. Frebourg, T. *et al.* Guidelines for the Li-Fraumeni and heritable TP53-related cancer
- 578 syndromes. *Eur J Hum Genet* **28**, 1379–1386 (2020).
- 579 5. Kratz, C. P. *et al.* Analysis of the Li-Fraumeni Spectrum Based on an International
- 580 Germline TP53 Variant Data Set: An International Agency for Research on Cancer
- 581 TP53 Database Analysis. *JAMA Oncology* **7**, 1800–1805 (2021).
- 582 6. Kastenhuber, E. R. & Lowe, S. W. Putting p53 in Context. *Cell* **170**, 1062–1078
- 583 (2017).
- 584 7. Kruiswijk, F., Labuschagne, C. F. & Vousden, K. H. p53 in survival, death and
- 585 metabolic health: a lifeguard with a licence to kill. *Nat Rev Mol Cell Biol* **16**, 393–405
- 586 (2015).
- 587 8. Levine, A. J. p53: 800 million years of evolution and 40 years of discovery. *Nat Rev*588 *Cancer* 20, 471–480 (2020).
- 589 9. Hainaut, P. & Pfeifer, G. P. Somatic TP53 Mutations in the Era of Genome Sequencing.
 590 *Cold Spring Harb Perspect Med* 6, a026179 (2016).
- 591 10. Stein, Y., Aloni-Grinstein, R. & Rotter, V. Mutant p53 oncogenicity: dominant-negative
 592 or gain-of-function? *Carcinogenesis* 41, 1635–1647 (2020).
- 593 11. Giacomelli, A. O. *et al.* Mutational processes shape the landscape of TP53 mutations
 594 in human cancer. *Nat Genet* 50, 1381–1387 (2018).
- 595 12. Kato, S. *et al.* Understanding the function-structure and function-mutation
- relationships of p53 tumor suppressor protein by high-resolution missense
- 597 mutation analysis. *Proc Natl Acad Sci U S A* **100**, 8424–8429 (2003).

- 598 13. Kotler, E. *et al.* A Systematic p53 Mutation Library Links Differential Functional
- Impact to Cancer Mutation Pattern and Evolutionary Conservation. *Mol Cell* **71**, 178190.e8 (2018).
- 601 14. Fortuno, C. *et al.* Specifications of the ACMG/AMP variant interpretation guidelines
- 602 for germline TP53 variants. *Hum Mutat* **42**, 223–236 (2021).
- 603 15. Mathe, E. *et al.* Computational approaches for predicting the biological effect of p53
- 604 missense mutations: a comparison of three sequence analysis based methods.
- 605 *Nucleic Acids Res* **34**, 1317–1325 (2006).
- 16. Ng, P. C. & Henikoff, S. Predicting deleterious amino acid substitutions. *Genome Res*11, 863–874 (2001).
- 608 17. Ben-Cohen, G. *et al.* TP53_PROF: a machine learning model to predict impact of
 609 missense mutations in TP53. *Brief Bioinform* 23, bbab524 (2022).
- 610 18. de Andrade, K. C. *et al.* The TP53 Database: transition from the International Agency
- 611 for Research on Cancer to the US National Cancer Institute. *Cell Death Differ* 1–3
- 612 (2022) doi:10.1038/s41418-022-00976-3.
- 613 19. Achatz, M. I. W. *et al.* The TP53 mutation, R337H, is associated with Li-Fraumeni and
- Li-Fraumeni-like syndromes in Brazilian families. *Cancer Lett* **245**, 96–102 (2007).
- 615 20. Indeglia, A. *et al.* An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of
- 616 p53-Mediated Tumor Suppression. *Cancer Discov* **13**, 1696–1719 (2023).
- 617 21. Pinto, E. M. *et al.* XAF1 as a modifier of p53 function and cancer susceptibility. *Sci Adv*618 6, eaba3231 (2020).
- 619 22. Yamazaki, F. et al. Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-
- 620 Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation. J
- 621 *Pediatr Hematol Oncol* **40**, e195–e197 (2018).

- 622 23. Yamaguchi, K. *et al.* Prevalence of low-penetrant germline TP53 D49H mutation in
- 623 Japanese cancer patients. *Biomed Res* **37**, 259–264 (2016).
- 624 24. Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant
- 625 variants. *Nucleic Acids Res* **44**, D862-868 (2016).
- 626 25. Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers,
- 627 educators, and developers. *Protein Sci* **30**, 70–82 (2021).
- 628 26. Chen, Y., Dey, R. & Chen, L. Crystal Structure of the p53 Core Domain Bound to a Full
- 629 Consensus Site as a Self-Assembled Tetramer. *Structure* **18**, 246–256 (2010).
- 630 27. Jeffrey, P. D., Gorina, S. & Pavletich, N. P. Crystal structure of the tetramerization
- 631 domain of the p53 tumor suppressor at 1.7 angstroms. *Science* **267**, 1498–1502
- 632 (1995).
- 633 28. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature*634 **596**, 583–589 (2021).
- 635 29. Tate, J. G. *et al.* COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids*636 *Research* 47, D941–D947 (2019).
- 637 30. Gudmundsson, S. *et al.* Variant interpretation using population databases: Lessons
- 638 from gnomAD. *Human Mutation* **n**/**a**,.
- 639

640 FIGURE LEGENDS

- 641
- 642 Figure 1: Summary / Graphical Abstract.
- 643

Figure 2: Distribution of *TP53* variants from YTA classes across *TP53* structure and datasets. A. Localization of *TP53* missense variants along the *TP53* sequence (left panel). Heatmap showing the number of variants found at each amino acid position, for each YTA classes. The *TP53* domains are indicated below the heatmap to visualize the localization of *TP53* variants within *TP53* secondary structure.

Proportion of residues within each TP53 domain for the four YTA classes (right panel). 649 650 **B.** Distribution of the variants from the YTA classes within different databases: 651 transactivation yeast assay, gnomAD database, Cosmic database, and IARC/NCI LFS dataset. Pie charts represent the number of samples with TP53 missense variants 652 653 belonging to the four YTA classes.

654

Figure 3: Relationship between YTA classes and clinical phenotype in the Li-655 656 Fraumeni Syndrome

657 **A.** Distribution of *TP53* germline carriers in the IARC/NCI database into classes. Class 658 0 includes non-missense variants (stop and frameshift). B. Sex distribution of 659 individuals (F=females, M=males) for each class. C. Cancer accrual of individuals 660 according to classes. The inverted Kaplan-Meier presentation corresponds to the age 661 of onset of the first cancer in each individual. The confidence intervals at 95% are displayed on the curves, and the p-value of the Log-Rank test is indicated. **D.** Pairwise 662 663 comparison of cancer accrual for each class. A multiple pairwise comparison (with 664 Bonferroni correction) shows the significance of differences in cancer accrual between 665 the classes (adjusted p-value). E. Median age of cancer accrual according to the 666 classes. The median age is indicated as a dot, and the confidence intervals at 95% are indicated by bars aside the dot. **F.** Proportion of individuals developing more than one 667 cancer during lifetime. For each class, the barplot displays the percentage of 668 669 individuals with more than one cancer. G. Proportion of cancer-free individuals. For each class, the barplot shows the percentage of individuals who did not develop any 670 cancer. **H.** Proportion of individuals with a germline variant in an established cancer 671 predisposing gene (CPG). For each class, the barplot shows the percentage of 672 individuals who carry a variant for a CPG other than TP53. I. Distribution of clinical 673 674 classes within TP53 classes. The proportion of individuals belonging to the following categories are displayed: Li-Fraumeni Syndrome (LFS), Li-Fraumeni like Syndrome 675 676 (LFL), Chompret criteria (TP53 Chompret), Familial History of cancer (FH), no Familial History of cancer (noFH), Other and Not Applicable (NA). J. Distribution of clinical 677 phenotypes of the LFS spectrum definition within TP53 classes. The proportion of 678 individuals belonging to the categories LFS, attenuated LFS, and incidental LFS are 679 displayed. Not only the P/LP TP53 variants are included. 680

Figure 4: Association of YTA classes with tumor spectrum in the Li-Fraumeni 682

683 **Syndrome.** A. Age-specific distribution of cancers (all topologies combined) for *TP53* classes. The rain-cloud plots display 1- a density plot showing distribution of age of 684 685 onset for cancers, 2- a box-plot showing median age of onset as well as guartiles and outliers values, and 3- a dot-plot showing every cancer analyzed. B. Distribution of 686 cancers by topology. The most frequent LFS topologies are displayed (adrenal gland, 687 brain, bones, soft tissues, hematopoietic system and breast); all other topologies are 688 referred as "other". Statistical comparisons are found in Table S2. C. Variation of 689 690 cancer topology within classes. Heatmap synthetizes cancer topology distribution from 691 Figure 4B (normalized in row by cancer topologies).

692

Figure 5: Heterogeneity of TP53 scores within YTA classes. Distribution of 693 694 functional scorings (phenotypic selection model and relative fitness score) into all 2,314 TP53 missense variants, subdivided by YTA classes. Violin plots and dot-plots 695 696 display the distribution of scores, and the median scores are indicated as white 697 triangles.

698

Figure 6: Concordance between YTA classes and ClinVar annotations. A. 699 700 Distribution of expert panel reviewed and non-expert panel reviewed TP53 variants in the ClinVar classification. Variants from the IARC/NCI TP53 germline database are 701 702 indicated in the pie chart. The second row of pie charts represents the breakdown of expert panel reviewed variants in ClinVar categories (Pathogenic, Likely Pathogenic, 703 704 Uncertain Significance, Likely Benign and Benign). Mapping of the YTA classes within 705 each ClinVar category is displayed. The number of variants for each ClinVar category 706 is indicated within each pie chart. B. Cancer accrual of each YTA class for the 707 subcategory of expert panel reviewed TP53 variants (top panel). The first cancer of the 708 NCI/IARC TP53 germline database is used to monitor cancer accrual. Confidence 709 intervals at 95% and Log-Rank test p-value are indicated. Median age of cancer 710 accrual according to the classes (bottom panel). The median age is indicated as a dot, 711 and the confidence intervals at 95% are indicated by bars aside the dot. **C.** Comparison 712 of cancer accrual for variants annotated by expert panel versus variants not annotated 713 by expert panel (No). Left panels show cancer accrual within each YTA class. Right panels display the median and confidence intervals. 714

Figure 7: Matching YTA classes to Li-Fraumeni clinical validation cohorts. For 716 717 each cohort, the patients' distribution into TP53 classes are shown in the pie charts (left panels), as well as the cancer accrual using the age of onset for the first cancer, 718 confidence intervals at 95% and Log-Rank p-values (right panels). A. Cohort 1 719 720 (France) analysis. B. Cohort 2 (Germany) analysis. C. Cohort 3 (Canada) analysis.

SUPPLEMENTARY FIGURE AND TABLE LEGENDS 721

722

723 Figure S1: Yeast Transactivation Assay (YTA) -based iterative clustering of the

724 **TP53 missense variants.** Transcriptional data from yeast-based assays consisting of 725 eight measurements for 2,314 TP53 missense variants were retrieved from Kato et al. 726 Three layers of Ward hierarchical clustering were applied to separate variants. For 727 each layer, heatmaps display the transactivation scores, and dendrograms represent 728 the clusters defined by hierarchical clustering.

729

Figure S2: Hierarchy of clusters and consolidation of TP53 variants classes. A. 730

731 Distribution of the 2,314 TP53 missense variants in clusters. Numbers of variants are 732 indicated in parenthesis above the cluster name. Color codes correspond to the 733 consolidation of classes explained in Fig S2B. B. Consolidation of classes. Class A 734 variants correspond to cluster 1 1 1; Class B variants correspond to 1 1 cluster except class A; Class C variants correspond to cluster 1 except classes A and B; Class 735 736 D variants correspond to all variants except classes A, B, and C. C. Distribution of transactivation scores within the consolidated classes. The heatmap displays scores 737 for all eight promoter measurements regarding all TP53 variants ranked by YTA 738 classes. **D.** Distribution of transactivation classes (non-functional, partially functional, 739 740 functional and supertrans) of TP53 variants within YTA classes based on hierarchical 741 clustering. Pareto plots display the number of TP53 variants belonging to the 742 transactivation classes.

743

Figure S3: Structural localization of variants from YTA classes. A. TP53 missense 744 variants located on Alpha-Fold *TP53* structural modeling. The TP53 germline variants 745 746 found in the IARC/NCI LFS database are separated by YTA classes and displayed on 747 the 3D structure. **B.** *TP*53 missense variants located on crystal-based structures of the 748 DNA binding domain (top panel) and oligomerization domain (bottom panel). TP53 germline variants found in the IARC/NCI LFS database are separated by YTA classesand displayed on the 3D structure.

751

Figure S4: Mapping of YTA classes to *TP53* scores. Pareto plots showing the
distribution of functional scorings for *TP53* variants (SIFT, AGVGD, and TP53 PROF)
within YTA classes.

755

Figure S5: Designing the TP53 variants class 0. A. Cancer accrual for all categories of non-missense variants in individuals from the IARC/NCI *TP53* variants germline database (LFS). **B.** Comparison of median age of cancer accrual (red dots) and confidence intervals (black lines) for the categories of non-missense variants. The nonsense and frameshift variants are selected for the design of a class 0.

761

Figure S6: Association of YTA classes with tumor spectrum in LFS. Distribution of cancers by morphology subtype. Histograms displaying the percentage of all cancers of individuals from IARC/NCI *TP53* variants germline database (LFS) with specific tumor morphologies evoking LFS.

766

Figure S7: YTA class specificities in the distribution of different topologies of
 cancers by age. Rain-cloud plots showing the age distribution of the following cancer
 topologies: adrenal gland, bones, breast, soft tissues, brain, hematopoietic, and all
 other topologies (other), for the individuals of classes 0, A, B and C in the IARC/NCI
 TP53 variants germline database (LFS). Class D was not considered as counts of
 cancers were not sufficient for analysis.

773

774 Figure S8: Challenging YTA classes with the phenotypic selection model score 775 in LFS. A. Distribution of the phenotypic selection model score from Giacomelli et al. 776 for each variant from the IARC/NCI TP53 variants germline database. For each YTA 777 class, dot-plots are annotated with the corresponding quartile values (25%; median; 75%) to design four groups (quartile 1, quartile 2, quartile 3, and quartile 4, from lowest 778 779 to highest values). B. Comparison of cancer accrual for individuals belonging to the four quartile groups in the same YTA class (left panels), and relationship between 780 median age of cancer accrual and guartiles (right panel). 781

Figure S9: Challenging YTA classes with the relative fitness score in LFS. A. 783

Distribution of the relative fitness score from Kotler et al. for each variant from the 784 785 IARC/NCI TP53 variants germline database. For each YTA class, dot-plots are 786 annotated with the corresponding quartile values (25%; median; 75%) to design four 787 groups (quartile 1, quartile 2, quartile 3, and quartile 4, from lowest to highest values). **B.** Comparison of cancer accrual for individuals belonging to the four guartile groups 788 in the same YTA class (left panels), and relationship between median age of cancer 789 790 accrual and quartiles (right panel).

791

792 Figure S10: Mapping YTA classes to the TP53 PROF classification. A. Distribution 793 of YTA classes in deleterious (D) and non-deleterious (ND) classes of the TP53_PROF model from Ben-Cohen et al. The number of variants from the *TP53* germline database 794 795 NCI/IARC is displayed. B. Cancer accrual of individuals separated by YTA classes, for 796 deleterious and for non-deleterious TP53 variants. Log-Rank p-values are indicated.

797

Figure S11: Association of YTA classes with tumor spectrum in Li-Fraumeni 798 799 clinical validation cohorts. Distribution of cancers by topology. The most frequent 800 LFS topologies are displayed (adrenal gland, brain, bones, soft tissues, hematopoietic system and breast); all other topologies are referred as "other"; cancer-free patients 801 802 are indicated as "no cancer". A. Cohort 1 (France) analysis. B. Cohort 2 (Germany) 803 analysis. C. Cohort 3 (Canada) analysis.

804

Table S1: TP53 missense variants and corresponding YTA classes. The 2,314 805 TP53 missense variants are annotated with the YTA classification (classes A, B, C, D), 806 807 as well as scores developed by others.

808

Table S2: Risk ratio of tumor localization for YTA classes in LFS. Statistical 809 significance of variation of tumor distribution (topology) for each pair-wise comparison 810 of YTA classes. Khi2 tests are reported in the table (risk ratio between the two classes, 811 with confidence intervals 95% and the adjusted p-value with Benjamini-Hochberg 812 correction for multiple comparisons), for the following topologies: adrenal gland, bones, 813 brain, breast, hematopoietic system, other, and soft tissues. Grey highlights 814 correspond to pairwise comparison that reached adjusted p-value <0.05. 815

Fine resolution clustering of *TP53* variants into functional classes predicts cancer risks and spectra among germline variant carriers

Emilie Montellier, PhD (1), Nathanaël Lemonnier, PhD (1), Judith Penkert, MD (2), Claire Freycon, MD (1,3,4), Sandrine Blanchet, MSc (1), Amina Amadou, PhD (1,5), Florent Chuffart, PhD (1), Nicholas Fischer, PhD (6), Maria Isabel Achatz, MD, PhD (7), Arnold Levine, PhD (8), Catherine Goudie, MD (4), David Malkin, MD, PhD (6), Gaëlle Bougeard, PhD (9), Christian Kratz, MD (2) and Pierre Hainaut, PhD (1)*

Affiliations:

(1) Univ. Grenoble Alpes, Inserm 1209, CNRS 5309, Institute for Advanced Biosciences, F38000, Grenoble, France

(2) Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

(3) Centre Hospitalier Universitaire Grenoble Alpes, Department of Pediatrics

(4) Department of Pediatrics, Division of Hematology-Oncology, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada

(5) Department of Prevention Cancer Environment, Centre Léon Bérard, Lyon, France

(6) Genetics and Genome Biology Program, The Hospital for Sick Children; University of Toronto, Toronto, Ontario, Canada

(7) Department of Oncology, Hospital Sírio-Libanês, São Paulo, Brazil

(8) Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ

(9) Department of Genetics, Normandy Center for Genomic and Personalized Medicine, University Hospital,

Rouen, France; Normandie Univ - UniRouen, Inserm U1245, Rouen, France

Correspondence:

 * corresponding author: Institute for Advanced Biosciences, Univ. Grenoble Alpes, Inserm 1209, CNRS 5309
 Site Santé, Allée des Alpes
 F38700, La Tronche, France
 pierre.hainaut@univ-grenoble-alpes.fr
 Tel +33 6 20 38 05 47

ABSTRACT

Li-Fraumeni syndrome (LFS) is a heterogeneous predisposition to a broad spectrum of cancers caused by pathogenic *TP53* germline variants. We have used a clustering approach to assign missense variants to functional classes with distinct quantitative and qualitative features based on transcriptional activity in yeast assays. Genotype-phenotype correlations were analyzed using the germline *TP53* mutation database (n = 3,446) and validated in three LFS clinical cohorts (n= 821). Carriers of class A variants recapitulated all traits of fully penetrant LFS (median age at first diagnosis = 28 years). Class B carriers showed a less penetrant form (median = 33 years, p < 0.05) dominated by adrenocortical and breast cancers. Class C or D carriers had attenuated phenotypes (median = 41 years, p < 0.001) with typical LFS cancers in C and mostly non-LFS cancers in D. This new classification provides insight into structural/functional features causing pathogenicity.



Figure 2

Α.

All TP53 missense variants (n=2,314) 100-Proportion of variants 75 Domains 4 в DNA.binding Other 50-2 Transactivation С Oligomerization 0 SH3.like.Pro.rich 25 0 Ċ Ď À B Classes Β. **Cosmic counts** Dataset IARC/NCI Kato yeast assay gnomAD counts (all TP53 missense (normal sample based (tumor based TP53 counts (TP53 TP53 variants) variants) variants) germline variants)

Frequency of variants



C 671 (29.0%) D 1033 (44.64%)



C 159 (13.2%) D 987 (82.1%)



B 3498 (10.0%) C 2389 (6.8%) D 1812 (5.1%)



Figure 3



Multiple pairwise comparison of cancer accrual

| Comparison | Adjusted_P_Value | Significance |
|------------|------------------|--------------|
| 0 vs. A | 1.00e+00 | NS |
| 0 vs. B | 4.37e-03 | ** |
| 0 vs. C | 1.74e-11 | *** |
| 0 vs. D | 1.68e-08 | *** |
| A vs. B | 2.08e-02 | * |
| Avs. C | 5.35e-11 | *** |
| Avs. D | 5.54e-08 | *** |
| B vs. C | 3.68e-03 | ** |
| B vs. D | 3.85e-03 | ** |
| C vs. D | 1.00e+00 | NS |





Years

25

0.0 Ó





Ď

G.

















Figure 6



40 50 Median Age Cancer Accrual

A. French cohort





Classes \bullet 0 \bullet A \bullet B \bullet C 1.00 0.75 0.50 0.25 0.00 0 20 40 60 Years

C. Canadian cohort





B. German cohort

